Skip to main content
Download PDF

Vaccine responses in patients with rheumatoid arthritis

Current Rheumatology Reports volume 9, pages 407–415 (2007)Cite this article

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease that is associated with immunologic alterations in T cells and B cells. Moreover, many of the agents used in RA patients are potentially immunosuppressive. Thus, the underlying disease and treatment may both increase the susceptibility to infections and decrease vaccine responses. With the growing use of aggressive therapies for RA, including anti-tumor necrosis factor agents and newer biologic therapies such as rituximab and abatacept, an increasing concern will be that patients may not respond to conventional vaccination. Further prospective studies on response to vaccination are needed to answer this important public health question. Nevertheless, it is already clear that vaccination does induce response in many patients. Unfortunately, vaccination is underutilized in RA patients and needs to be aggressively promoted.

References and Recommended Reading

  1. Verwilghen J, Vertessen S, Stevens E, et al.: Depressed T cell reactivity to recall antigens in rheumatoid arthritis. J Clin Immun 1990, 10:90–98.

    PubMed  Article  CAS  Google Scholar 

  2. Berg L, Lampa J, Rogberg S, et al.: Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 2001, 60:133–139.

    PubMed  Article  CAS  Google Scholar 

  3. Koetz K, Bryl E, Spickschen K, et al.: T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci 2000, 97:9203–9208.

    PubMed  Article  CAS  Google Scholar 

  4. Schonland S, Lopez C, Widmann T, et al.: Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. Proc Natl Acad Sci 2003, 100:13471–13476.

    PubMed  Article  CAS  Google Scholar 

  5. Looney RJ, Hasan MS, Coffin D, et al.: Hepatitis B immunization of healthy elderly adults: relationship between naive CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol 2001, 21:30–36.

    PubMed  Article  CAS  Google Scholar 

  6. Govaert TM, Thijs CT, Masurel N, et al.: The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994, 272:1661–1665.

    PubMed  Article  CAS  Google Scholar 

  7. Ehrenstein M, Evans J, Singh A, et al.: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004, 200:277–285.

    PubMed  Article  CAS  Google Scholar 

  8. Doran MF, Crowson CS, Pond GR, et al.: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46:2287–2293.

    PubMed  Article  Google Scholar 

  9. Doran M, Crowson C, Pond G, et al.: Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002, 46:2294–2300.

    PubMed  Article  Google Scholar 

  10. Wolfe R, Caplan L, Michaud K, et al.: Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Arthritis Rheum 2006, 54:628–634.

    PubMed  Article  CAS  Google Scholar 

  11. Bongartz T, Sutton A, Sweeting M, et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006, 295:2275–2285.

    PubMed  Article  CAS  Google Scholar 

  12. Kremers H, Bidaut-Russell M, Scott C, et al.: Preventive medical services among patients with rheumatoid arthritis. J Rheum 2003, 30:1940–1947.

    PubMed  Google Scholar 

  13. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46(RR-8):1–24.

  14. Harper SA, Fukuda K, Uyeki TM, et al.: Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54(RR-8):1–40.

    PubMed  Google Scholar 

  15. Sztein M: Recent advances in immunology that impact vaccine development. In New Generation Vaccines. Edited by Levine M, Kaper J, Rappuoli R, et al. New York: Marcel Dekker; 2004:159–178.

    Google Scholar 

  16. Eskola J, Black S, Shinefield H: Pneumococcal conjugate vaccines. In Vaccine. Edited by Plotkin SA, Orenstein WA. Philadelphia: Saunder; 2004:589–624.

    Google Scholar 

  17. Black S, Shinefield H, Fireman B, et al.: Efficacy, safety, and immunogenicity of a heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19:187–195.

    PubMed  Article  CAS  Google Scholar 

  18. Kapetanovic MC, Saxne T, Sjoholm A, et al.: Influence of methotrexate, TNF blockers, and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology 2006, 45:106–111.

    PubMed  Article  CAS  Google Scholar 

  19. O’Dell J, Gilg J, Palmer W, et al.: Pneumococcal vaccine in rheumatoid arthritis: Decreased response while taking methotrexate. J Clin Rheumatol 1996, 2:59–63.

    Article  Google Scholar 

  20. Elkayam O, Paran D, Caspi D, et al.: Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002, 34:147–153.

    PubMed  Article  Google Scholar 

  21. Elkayam O, Caspi D, Reitblatt T, et al.: The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004, 33:283–288.

    PubMed  Article  CAS  Google Scholar 

  22. Kasapcopur O, Koca B, Asian M, et al.: Pneumococcal vaccine response and antibody levels in juvenile idiopathic arthritis. Ann Rheum Dis 2006, 65(Suppl II):112.

    Google Scholar 

  23. Visvanathan S, Weiss R, Keenan G, et al.: Response to the pneumococcal vaccine in patients with early rheumatoid arthritis. Ann Rheum Dis 2005, 64(Suppl III):422.

    Google Scholar 

  24. Kaine J, Kivitz A, Birbara C, et al.: Effect of adalimumab on response to influenza virus and pneumococcal vaccines in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65(Suppl II):304.

    Google Scholar 

  25. Mease PJ, Ritchlin CT, Martin RW, et al.: Pnemococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004, 31:1356–1361.

    PubMed  CAS  Google Scholar 

  26. Romero-Steiner S, Frasch CE, Carlone G, et al.: Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006, 13:165–169.

    PubMed  Article  CAS  Google Scholar 

  27. Treanor J, King J, Zangwill K: New approaches to influenza vaccine. In New Generation Vaccines. Edited by Levine M, Kaper J, Rappuoli R, et al. New York: Marcel Dekker; 2004:537–558.

    Google Scholar 

  28. Vu T, Farish S, Jenkins M, et al.: A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002, 20:1831–1836.

    PubMed  Article  Google Scholar 

  29. Fukuda K, Levandowski R, Bridges C, et al.: Inactivated influenza virus. In Vaccines. Edited by Plotkin SA, Orenstein WA. Philadelphia: Saunder; 2004:339–370.

    Google Scholar 

  30. Fomin I, Caspi D, Levy V, et al.: Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFalpha blockers. Ann Rheum Dis 2006, 65:191–194.

    PubMed  Article  CAS  Google Scholar 

  31. van der Bijl AE, Gelinck LB, Breedveld FC, et al.: Anti-TNF alpha inhibits the antibody response to influenza vaccination. Ann Rheum Dis 2005, 64(Suppl III):181.

    Google Scholar 

  32. Kapetanovic M, Saxne T, Nilsson J: Influenza vaccination as model for testing immune modulation of anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Ann Rheum Dis 2006, 65(Suppl II):184.

    Google Scholar 

  33. Herron A, Kettleff G, Hixon B, et al.: Influenza vaccination in patients with rheumatic diseases JAMA 1979, 242:53–56.

    PubMed  Article  CAS  Google Scholar 

  34. Chalmers A, Scheifele D, Patterson C, et al.: Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994, 21:1203–1206.

    PubMed  CAS  Google Scholar 

  35. Del Porto F, Lagana B, Biselli R, et al.: Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis; safety and immunogenicity. Vaccine 2006, 24:3217–3223.

    PubMed  Article  CAS  Google Scholar 

  36. Malleson P, Tekano J, Scheifele D, et al.: Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol 1993, 20:1769–1773.

    PubMed  CAS  Google Scholar 

  37. Mast E, Mahoney F, Kane M, et al.: Hepatitis B vaccine. In Vaccine. Edited by Plotkin SA, Orenstein WA. Philadelphia: Saunders; 2004:299–337.

    Google Scholar 

  38. Collier AC, Corey L, Murphy VL, et al.: Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccine. Ann Intern Med 1988, 109:101–105.

    PubMed  CAS  Google Scholar 

  39. Elkayam O, Yaron M, Caspi D: Safety and efficacy of vaccination against Hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002, 61:623–625.

    PubMed  Article  CAS  Google Scholar 

  40. Kasapcopur O, Cullu F, Kamburoolu-Goksel, et al.: Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis 2004, 63:1128–1130.

    PubMed  Article  CAS  Google Scholar 

  41. Maillefert JF, Sibilia J, Toussirot E, et al.: Rheumatic disorders developed after hepatitis B vaccination. Rheumatology 1999, 38:978–983.

    PubMed  Article  CAS  Google Scholar 

  42. Pope J, Stevens A, Howson W, et al.: The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J Rheumatol 1998, 25:1687–1693.

    PubMed  CAS  Google Scholar 

  43. Matsumoto M, Fu YX, Molina H, Chaplin DD: Lymphotoxin-alpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers. Immunol Rev 1997, 156:137–144.

    PubMed  Article  CAS  Google Scholar 

  44. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G: Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996, 184:1397–1411.

    PubMed  Article  CAS  Google Scholar 

  45. Anolik JH, Owen T, Barnard J, Sanz I: Anti-TNF therapy in RA alters B lymphocyte dynamics [abstract]. Presented at the American College of Rheumatology Annual Meeting. San Francisco; November 13–17, 2005.

  46. Fu YX, Chaplin DD: Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 1999, 17:399–433.

    PubMed  Article  CAS  Google Scholar 

  47. Looney RJ, Anolik JH, Sanz I: B-cells as therapeutic targets for rheumatic disease. Curr Opinion Rheum 2004, 16:180–185.

    Article  CAS  Google Scholar 

  48. Looney RJ: New therapies for systemic lupus erythematosus: cellular targets. Rheum Dis Clin North Am 2006, 32:201–215.

    PubMed  Article  Google Scholar 

  49. Van der Kolk LE, Baars JW, Prins MH, et al.: Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002, 10:2257–2259.

    Google Scholar 

  50. Bearden CM, Agarwal A, Book BK, et al.: Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 2005, 5:50–57.

    PubMed  Article  CAS  Google Scholar 

  51. Oren C, Mendelbaum M, Paran D, et al.: Vaccination against influenza in rheumatoid arthritis patients: the effect of rituximab on the humoral response [abstract]. Presented at the European League Against Rheumatism (EULAR) Meeting. Amsterdam; June 21–24, 2006.

  52. Looney RJ: B-cell targeted therapy for RA. Drugs 2006, 66:1–16.

    Article  Google Scholar 

  53. Abrams J, Lebwohl M, Guzzo C, et al.: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243–1252.

    PubMed  CAS  Article  Google Scholar 

  54. Corbo M, Tay L, Leon F, et al.: A single dose of abatacept does not prevent the development of a positive immune response to tetanus and pneumococcal vaccines. Ann Rheum Dis 2006, 65(Supp II):184.

    Google Scholar 

Download references

Author information

Affiliations

  1. University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY, 14642, USA

    R. John Looney

Authors
  1. Rajan Ravikumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Anolik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. John Looney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. John Looney.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ravikumar, R., Anolik, J. & Looney, R.J. Vaccine responses in patients with rheumatoid arthritis. Curr Rheumatol Rep 9, 407–415 (2007). https://doi.org/10.1007/s11926-007-0065-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0065-3

Keywords

  • Rheumatoid Arthritis
  • Etanercept
  • Juvenile Idiopathic Arthritis
  • Adalimumab
  • Abatacept